Commentary: Time for progressive action

Shifts in the way Congress and the White House talk about the drug industry in recent months have created an opportunity for change that biotech and pharma companies, patient advocates and investors should quickly seize.

The conversation has moved from agonizing over how to regulate all risks out of drugs - an impossible goal - to how better regulation can stimulate the creation of new, highly effective medicines for patients with serious unmet needs...